

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/715,417 Confirmation No.: 5850  
Applicant : Eivind Per Thor STRATEN *et al.*  
Filed : November 19, 2003  
Title : SURVIVIN-DERIVED PEPTIDES AND USE THEREOF  
TC/Art Unit : 1644  
Examiner: Marianne DiBrino, Ph.D.  
  
Docket No. : 60820.000004  
Customer No. : 21967

**MAIL STOP AMENDMENT**

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

LETTER REGARDING SUBSTANCE OF INTERVIEW

Sir,

In accordance with 37 C.F.R. § 1.133(b) and M.P.E.P. § 713.04, Applicants herein provide a summary of the personal interview of June 26, 2008 between Robin Teskin, Robert Lampe, III, and Examiner Marianne DiBrino, Ph.D. Applicants appreciate the courtesies extended by the Examiner during this interview. During the interview, the rejections of record were discussed. The rejections under 35 U.S.C. § 112, 1<sup>st</sup> and 2<sup>nd</sup> paragraph concerning the cell lines recited in claim 24 were discussed, and Applicant may introduce additional information concerning the cell lines, such as commercial availability. The Examiner suggested (for the claims drawn only to the peptide) adding functional language in order to potentially overcome the written description rejection of record. The prior art rejections based on the Anderson references were discussed, and no agreement was reached.

Respectfully submitted,

HUNTON & WILLIAMS LLP

*Patent Application No. 10/715,417*

*E.P.T. Stratet et al.*

*July 28, 2008*

*Attorney Docket No. 60820.000004*

Dated: July 28, 2008

By:



Robin L. Teskin

Reg. No. 35,030

Robert C. Lampe III  
Registration No. 51,914

HUNTON & WILLIAMS LLP  
Intellectual Property Department  
1900 K Street, N.W., Suite 1200  
Washington, DC 20006-1109  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)